Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MC-Val-Cit-PAB-MMAF
- Development stage
- Preclinical
- Lead developer
- Chongqing Sintaho Pharmaceutical
- Modality
- Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
MC-Val-Cit-PAB-MMAF is a linker-payload intermediate used in the construction of antibody-drug conjugates (ADCs). It consists of the cytotoxic agent monomethyl auristatin F (MMAF) conjugated to a maleimidocaproyl (MC) cap via a cathepsin B-cleavable valine-citrulline (Val-Cit) dipeptide and a self-immolative p-aminobenzyloxycarbonyl (PAB) spacer. MMAF is a potent tubulin inhibitor that disrupts microtubule polymerization, leading to cell cycle arrest and apoptosis. The Val-Cit-PAB linker system is designed to be stable in systemic circulation but rapidly cleaved by lysosomal proteases upon internalization into target cancer cells. Chongqing Sintaho provides this intermediate as part of its XDC toxin-linker platform for ADC development.
- Other names
- mc-vc-PAB-MMAFMaleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl-monomethyl auristatin F
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on MC-Val-Cit-PAB-MMAF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MC-Val-Cit-PAB-MMAF.